Qualigen Therapeutics Inc... (QLGN)
NASDAQ: QLGN
· Real-Time Price · USD
1.87
0.11 (6.01%)
At close: Aug 15, 2025, 3:42 PM
Company Description
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases.
It offers FastPack, a rapid diagnostic testing system.
The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood.
Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 23, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Kevin A. Richardson II |
Contact Details
Address: 2042 Corte Del Nogal Carlsbad, California United States | |
| Website | https://qlgntx.com |
Stock Details
| Ticker Symbol | QLGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001460702 |
| CUSIP Number | 74754R103 |
| ISIN Number | US74754R3012 |
| Employer ID | 26-3474527 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin A. Richardson II | Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board |
| Michael S. Poirier | Chief Operating Officer |
| Christopher L. Lotz | Vice President of Finance & Corporate Secretary |
| Robert W. Campbell Becher | President & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | D | Filing |
| Aug 07, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 28, 2025 | 8-K | Current Report |
| Jul 28, 2025 | 8-K | Current Report |
| Jul 21, 2025 | 10-Q | Quarterly Report |
| Jul 16, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 10-K | Annual Report |
| Jun 24, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |